Yes, bulk Urolithin A is a natural polyphenolic compound produced by the metabolism of ellagic acid and ellagic tannin by intestinal microbiota. It has become a research hotspot in the field of aging intervention by inducing mitochondrial autophagy through activation of the PINK1/Parkin signaling pathway. So why does urolithin A reverse aging?
Why Does Urolithin A Reverse Aging?
Mitochondrial Autophagy Activation Mechanism
The core mechanism of action of bulk Urolithin A lies in its activation of the PINK1/Parkin signaling pathway, thereby facilitating the clearance of functionally impaired mitochondria. This process is crucial for maintaining cellular energy metabolism homeostasis. Studies have shown that Urolithin A treatment can enhance metabolic functions such as the tricarboxylic acid cycle, fatty acid oxidation, and oxidative phosphorylation.
During aging, the efficiency of mitophagy declines, leading to the accumulation of reactive oxygen species (ROS) and exacerbated cellular damage. Urolithin A intervenes in the aging process at the organelle level by restoring mitochondrial quality control mechanisms.
Anti-inflammatory and Antioxidant Effects
In addition to promoting mitophagy, bulk Urolithin A also possesses multi-target anti-inflammatory activities. Studies have shown that it can inhibit the nuclear factor kappa B (NF-κB) and protein kinase B/mitogen-activated protein kinase (Akt/MAPK) signaling pathways, upregulate anti-inflammatory factors such as interleukin-10 (IL-10) and transforming growth factor-β1 (TGF-β1), and downregulate pro-inflammatory factors such as tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β).
In terms of antioxidant activity, bulk Urolithin A can enhance the activity of endogenous antioxidant enzymes such as catalase (CAT), superoxide dismutase (SOD), and glutathione peroxidase (GPx), while reducing ROS levels.
Neuroprotection and Immunomodulation
Urolithin A shows potential for application in neurodegenerative diseases. Research by Hou Yujun's team at Tongji University has shown that long-term administration of Urolithin A can improve learning, memory, and olfactory functions in Alzheimer's disease (AD) model mice, while reducing β-amyloid (Aβ) deposition and tau protein pathology in the brain. Mechanistic studies reveal that Urolithin A restores lysosomal function by regulating cathepsin Z (CTSZ), thereby inducing mitophagy.
In the field of immunosenescence, a clinical study published in Nature Aging found that daily supplementation with urolithin A bulk powder natural sources improved the function and composition of key immune cells in middle-aged individuals, and a decrease in inflammatory markers was observed after a 4-week intervention.
Evidence from Human Clinical Trials
• Overview of Systematic Reviews
A systematic review published up to May 2023 included 5 studies involving a total of 250 healthy subjects, with intervention doses ranging from 10 to 1000 mg/day and durations ranging from 28 days to 4 months. Key findings included that bulk Urolithin A exhibited a dose-dependent anti-inflammatory effect, upregulated the expression of certain mitochondrial genes, autophagy markers, and fatty acid oxidation-related genes. Regarding functional outcomes, Urolithin A increased muscle strength and endurance but had no significant effect on anthropometric parameters, cardiovascular outcomes, or overall physical function.
• Targeted Intervention for Muscle Aging
Muscle aging is the most well-established indication in Urolithin A bulk research. A study involving healthy adults aged 65–90 years showed that 4 months of Urolithin A supplementation (1000 mg/day) improved muscle endurance. Another study involving overweight, low-activity individuals aged 40–65 years reported similar results.
A Japanese study using low doses (10–50 mg/day) also observed improvements in muscle function, suggesting that Urolithin A may exhibit biological activity across a wide dose range.
• Ongoing Cutting-Edge Research
As of 2026, several clinical trials related to Urolithin A are underway. A randomized controlled trial at Huazhong University of Science and Technology is evaluating the effects of bulk Urolithin A (500 mg/day) in combination with fisetin on sleep quality and aging biomarkers in middle-aged and elderly individuals. This study will also examine indicators such as DNA methylation (the epigenetic clock), inflammatory factors, and gut microbiota.
Furthermore, a pharmacokinetic study investigating the bioavailability of different formulations of pure Urolithin A was completed in March 2026 and is expected to provide important data for formulation optimization.
Challenges and Limitations
Oral Bioavailability Issues
A core challenge to the clinical application of Urolithin A is its low oral bioavailability. Pharmacokinetic studies show limited plasma exposure of Urolithin A bulk powder under standard dosing regimens. To overcome this issue, formulation strategies such as nanoparticles and liposomes have been developed, which can improve systemic bioavailability several-fold compared to unencapsulated Urolithin A powder.
Individual Metabolic Differences
Approximately 40% of adults are capable of producing Urolithin A after ingesting pomegranate juice, and direct supplementation with 500 mg of Urolithin A can increase plasma levels by more than six times compared to drinking pomegranate juice.
However, approximately 10% of individuals are classified as "Urolithin A non-producers," and this proportion is not related to age. This phenomenon suggests that, for some populations, direct supplementation with Urolithin A is a necessary strategy to bypass gut microbiota limitations.
Safety Evaluation
All adverse events reported in existing clinical trials were mild to moderate, with no significant difference from the placebo group, and were determined to be unrelated to the study intervention. Urolithin A demonstrated good safety and tolerability within the recommended dosage range.
How To Use Urolithin A in formulation?
Improve bioavailability with lipid carriers
Urolithin A powder has relatively low oral bioavailability, so formulation strategies should focus on improving absorption. It can be combined with lipid-based delivery systems such as liposomes, nanoemulsions, softgels, or microencapsulation technologies. These approaches help enhance stability, increase absorption efficiency, and improve systemic bioavailability.
Combine with anti-aging ingredients for synergistic effects
Urolithin A bulk powder can be formulated with other functional ingredients to create synergistic anti-aging benefits. Common combination options include fisetin, resveratrol, NMN, coenzyme Q10, and PQQ. Such combinations may better support mitochondrial function, cellular repair, antioxidant defense, and healthy aging.
Develop targeted formulations for different populations
Different consumer groups require different dosage strengths and formulation designs.
Elderly individuals: focus on muscle endurance, mitochondrial health, and healthy aging support
Athletes and active consumers: focus on recovery, energy metabolism, and physical performance
Immunocompromised or high-stress groups: focus on immune support and antioxidant protection
Choose suitable dosage forms
Urolithin A can be developed into capsules, tablets, powders, sachets, or liquid formulations depending on the target market and application scenario.
Is Urolithin A Safe?
Yes, currently, Urolithin A bulk powder is sold as a dietary supplement in major markets such as the US and Europe. The approval process for "new food ingredients" in the Chinese market also warrants attention.
Raw material Urolithin A suppliers should assist clients in preparing all necessary technical documentation for compliance, including quality standards and safety assessment data.
Conclusion
Urolithin A demonstrates strong potential in delaying aging and related disease progression through multiple mechanisms, including activating mitophagy, inhibiting inflammation, and mitigating oxidative stress.
Human clinical trials have confirmed its effectiveness in improving muscle function and regulating immune aging, with a good safety profile. However, low bioavailability and individual metabolic differences remain major obstacles to its widespread application.
For B2B customers in the anti-aging supplement industry, choosing a raw material partner with large-scale production capabilities, a rigorous quality control system, and formulation development support is crucial to seizing this market opportunity.
Guanjie Biotech focuses on the research, development, and production of Urolithin A powder and is committed to providing innovative, high-quality raw material products to global clients. Our client network covers more than 100 countries, providing end-to-end services from raw material supply to formulation support. For inquiries, please contact: info@gybiotech.com.
References:
[1] Yang Zijiang, Guo Chenggen, Deng Ziao, et al. Postbiotic targeting muscle aging: mechanistic insights and application prospects of urolithin A. Chinese Journal of Tissue Engineering Research, 2026, 30(22): 5804-5813.
[2] Hou YJ, Bohr VA, et al. Urolithin A improves Alzheimer's disease cognition and restores mitophagy and lysosomal functions. Alzheimer's & Dementia, 2024.
[3] Chen LK, et al. Evaluation of Urolithin A and Fisetin on Improving Sleep and Aging Biomarkers in Middle-Aged and Older Adults: A Randomized Controlled Trial. ClinicalTrials.gov ID: NCT06990256, 2026.
[4] Yuan HD, et al. Urolithin A From Gut Metabolite to Therapeutic Agent: Bioavailability, Mechanisms, and Translational Insights. J Food Sci, 2026.
[5] Timeline SA. Mitopure® Clinical Development Overview. PharmaNX, 2025.
[6] Liu S, et al. Targeting aging with urolithin A in humans: A systematic review. Ageing Research Reviews, 2024, 100: 102406.
